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Left ventricular assist devices (LVADs) offer live-saving therapy to transplant-ineligible heart failure 
patients.  A major limitation of the technology includes pump thrombosis, bleeding, and recurrent 
infection that prove difficult to predict from in vivo animal testing. Shear stress introduced by the LVAD 
affects more than just haemolysis since platelets, leukocytes, and plasma proteins all contribute to the 
propensity for complications. It is important to assess overall damage by a new device against a base 
line as early as possible in the development process so that design iterations can be made if required.  
Methods:  
Explanted VADs currently in clinical use (HeartMate 2 and HVAD) were carefully cleaned, inspected, 
and run at 5 L/min and pressure at 100 mmHg in a standard 500 mL mock circulatory loop using bovine 
blood. The CentriMag was used as a control pump due to its low blood damage profile. Samples were 
collected at regular intervals and the following analysed: complete cell counts; haemolysis; platelet 
activation; leukocyte-derived microparticles (LMPs); and von Willebrand factor (vWF) degradation.  
Results:  
The HeartMate 2 had the highest levels of haemolysis and platelet activation after 6 hours compared to 
the HVAD and CentriMag. A decreased granulocyte count, high numbers of LMPs and 
CD11bBrightHLADR- LMPs, and decreased vWF collagen binding activity was most evident in the 
HVAD.  
Conclusions: 
The results indicate that it is possible to observe differences between different pump designs during in 
vitro testing that might translate to clinical performance. This study demonstrates the importance of 
developing standard in vitro total blood damage methods against which device developers could use to 





Heart failure (HF) currently affects at least 26 million people worldwide (1) with a 25% expected 
increase in prevalence by 2030 (2). Healthcare costs for chronic heart failure (CHF) accounts for around 
2% of the UK NHS expenditure (3) and $30 billion per year in the USA (4). The cure for HF is a heart 
transplant which has excellent 1-year (93%) and 5-year survival (88%), and functional capacity (5). 
However, with only approximately 7000 global transplants performed annually (6) and a vast majority 
of patients classed as ineligible for transplant due to age, weight, and comorbidities (7), there is great 
need for an effective long-term alternative therapy.  
Implantable left ventricular assist devices (LVADs) have emerged as mainstream treatment for severely 
symptomatic heart failure in selected non-transplant eligible patients (8, 9). Survival data from 
INTERMACS suggest LVAD outcomes now rival transplantation particularly in patients with 
ischaemic cardiomyopathy (10). Pump thrombosis was once a persistent, major limitation of this 
technology (11) however newer designs have managed to eradicate this (12). Despite improvement in 
thrombosis, other complications such as GI bleeding, and LVAD-related infection still remain 
problematic (13) and might be difficult to predict from in vivo testing in sheep or calves. Nonetheless, 
extensive pre-clinical testing is mandatory prior to clinical application of any new LVAD (12) with as 
much as possible learnt from in vitro work before any animal studies. Haemocompatibility testing plays 
a major role in this but the shear stress encountered by blood in transit through a rotary pump can affect 
other cell types and large proteins in the plasma (14). Therefore, blood testing requires more than 
evaluation of haemolysis since platelets, leukocytes and plasma proteins all contribute to the propensity 
for infection, gastrointestinal bleeding and thrombus formation (15-18). It is important to assess overall 
damage by a new device against a base line as early as possible in the development process so that 
design iterations can be made if required.  
Current temporary extracorporeal blood pumps, such as the widely used CentriMag® centrifugal pump 
(CP), may cause less blood damage than implanted LVADs because of the lack of size constraints. 
Extracorporeal use allows for larger slower moving rotors which provide lower shear stress. Combined 




extracorporeal blood pumps a good choice as a baseline control for incorporation into a disposable test 
loop for in vitro haemocompatibility testing.  
Previously, we have created a blood damage profile of the CentriMag® using assays including 
haemolysis, haematology (blood cell counts), white blood cell microparticles and von Willebrand factor 
(vWF) degradation (19). This showed very low haemolysis levels (NIH of 0.0011 g/100L), no changes 
in blood cell counts, but an increase in white blood cell microparticles and degradation of vWF. As the 
CentriMag pump has widespread clinical use, it is a good baseline control to compare the implantable 
LVADs against. Blood damage on par with the CentriMag can be considered clinically acceptable 
whereas significant increases in damage could go some way to explain clinical complications for 
specific pumps designs.  
The purpose of this study was to compare the blood damage profiles of the CentriMag, the HeartMate 
2 (HMII) and the HVAD, using the assays developed in house for haemolysis, haematology, white 







Preparation of test blood 
Blood was collected and prepared as described previously (19). Bovine peripheral blood was collected 
from the carotid artery during slaughter by gravity-filling a bottle primed with 14% citrate phosphate 
dextrose adenine (CPDA-1) anticoagulant and 50 mg/L gentamycin and 10 mL/L antimycotic solution 
(Sigma-Aldrich, Poole, UK). The blood was diluted with phosphate buffered saline (PBS, Life 
Technologies, Paisley, UK) as required to reach a haematocrit of 30 ± 2% to standardise samples (22). 
The blood was used in the experiments within 4 hours of collection.  
Device operation and specifications 
The following VADs were included in the study: 3 x HVAD (Medtronic, Framingham, MA, US), 3 x 
HMII and CentriMag CP (Abbott, Thoratec, Pleasanton, CA, US). The CentriMag CP used throughout 
this test was used directly out of packaging and used exclusively for in vitro testing with bovine blood. 
Explanted HMII and HVAD were subjected to rigorous cleaning to ensure no biological matter 
remained that could affect the test. The cleaning process involved sonication of the pumps in 5% 
Neutracon solution (Decon Laboratories, Location) at 50°C for 10 min, followed by a dH2O rinse then 
submerged briefly in 100% ethanol to remove water and allowed to dry. All pumps were tested using 
an in vitro test circuit under constant haemodynamic conditions in accordance with ASTM Standards 
as described previously by our group (19).  
Haemolysis assay 
Haemolysis was measured using the Harboe assay as described previously (20). The CentriMag has a 
very low and reproducible level of haemolysis (19). Static blood contained in a bag in a +37°C water 
bath was included as a negative control in each experiment. 
Automated haematology analysis 
Complete blood counts were measured using the veterinary analyser Abacus Jr Vet 5 (Diatron, 





A positive control for platelet activation was created by treating a baseline blood sample with 4 μM 
phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) for 60 min at room temperature with gentle 
agitation. To fix the activated platelets, 100 µL of PMA-treated blood was added to 100 µL Streck Cell 
Preservative (Streck Laboratories, City, CA, US), inverted 10 times and stored over night at +4°C. 
Baseline blood along with blood samples collected at time points 5, 120, 240, and 360 min were fixed 
in the same way. 20 μL of fixed blood was stained with CAPP2a (1.0 mg/dL, an anti-ruminant CD41/61 
antibody (23)) and analysed using flow cytometry as described previously (19). CAPP2a is expressed 
on resting inactivated platelets and decreased with platelet activation. Activated platelets were noted as 
CAPP2a-negative (CAPP2a-) events. 
Leukocyte microparticles 
Blood samples from time points 5, 120, 240, and 360 min were analysed for CD45+ microparticles as 
described previously by our group (24). To characterise the leukocyte microparticles, samples were also 
stained with a panel including lineage and activation markers. The antibodies used were anti-CD11b-
FITC (AbD Serotec, Oxford, UK), anti-CD21-PE (AbD Serotec), anti-CD14-BDV500 (BD Bioscience, 
Oxford, UK), anti-HLADR-PE-Cy7 (eBioscience, Hatfield, UK), MM1A for bovine T cells and 
MM20A for bovine granulocytes (both from WSUMAC, Pullman, WA, USA). These antibodies were 
conjugated in the lab using Lightning Link APC kit for MM1A (Novus Biologicals, Abingdon, UK) 
and the Zenon Pacific Blue Conjugation Kit for MM20A (Life Technologies) according to the 
manufacturers’ instructions. 
All samples were acquired with a Navios flow cytometer equipped with three lasers (violet: 405 nm, 
blue: 488 nm, red: 638 nm), the standard filter configuration, and with Navios Cytometry List Mode 
Data Acquisition and Data Analysis Software Navios Cytometer 1.2 software (Beckman Coulter, High 
Wycombe, UK). Forward scatter (FSC), side scatter (SSC), and fluorescent voltages were set using 
unstained samples and all samples were recorded for 60 sec. Stained AbC bead samples were acquired 
using a gate around the beads and capturing 10,000 events. Analysis was performed in Kaluza 1.5a 




The instrument was maintained using daily cleaning procedures recommended by the manufacturer 
throughout the study period. The quality control used the Flow-Check and Flow-Set Pro Fluorospheres 
(Beckman Coulter) and the protocols used were set-up by the manufacturer’s technical support 
engineers. 
vWF collagen binding activity 
The vWF collagen binding activity (vWF:CBA) in the samples was assessed using a Zymutest 
vWF:CBA enzyme-linked immunosorbent assay (ELISA). Absorbance was measured at 450 nm 
(POLARstar Omega) and standardised to the static control. 
vWF immunoblotting 
To visualise vWF multimers, platelet-poor plasma (PPP) was prepared by centrifuging 1 mL aliquots 
of whole blood at 4700 x g for 7 min. The supernatant (PPP) was removed into a separate tube for 
analysis. Samples were fractionated under non-reducing conditions using sodium dodecyl sulphate 
(SDS)-agarose gel electrophoresis, transferred onto polyvinylidene difluoride (PVDF) membrane and 
probed using anti-vWF antibody. 
Statistical methods and analysis 
Averages and standard deviations were calculated for all parameters and time points. For haemolysis 
and platelet activation, the background levels observed at 5 minutes were subtracted from all other 
measurements. Leukocyte microparticles and complete blood counts were divided by the static control 
at time point 5 minutes to evaluate the relative increase or decrease caused by duration of pumping 
whilst minimising donor-to-donor variability. For haematology, vWF immunoblotting and vWF:CBA, 
the data were expressed as a percentage of the static 5 minute control The dataset consisted of repeated 
measurements of blood samples across three pumping conditions and 4-7 time points (7 for haemolysis, 
4 for the other assays).  
Since the differences between the different pumps were so stark and changes monotonic and cumulative 
we felt that complex models were unnecessary. Since damage is cumulative we performed a simple 




performed using least significant difference (LSD), which is both simple to interpret and appropriate 
for such a small number of groups. Difference between pumps were reported as effect size (η2) and as 
a 95% confidence interval. Temporal trends were tested using Linear Regression. A 5% level of 
significance was used throughout. All statistical data analysis was performed in IBM SPSS version 25 
(SPSS, Inc., Chicago, Illinois, US). 
Exclusion criteria 
Any tests during which the flow rate failed to meet the target range (4.75 – 5.25 L/min) were excluded 
from further analysis. The CentriMag pump was used in each test as a control of the experimental 
conditions. If the normalised index of haemolysis (NIH) value for the CentriMag after completion of 
the test was ≥0.002 g/ 100 L, the blood was considered of low quality and the experiment (including all 
data from the haematology analyser and flow cytometry assays) was excluded from the analysis.  Tests 
where the platelets did not activate in response to chemical stimulation with PMA were excluded. 
Results 
Haemolysis 
NIH in both the HMII (n = 12) and the HVAD (n = 11) at 360 min was significantly higher than in the 
CentriMag (n = 25) (p < 0.0001; Figure 1A). The NIH is calculated from the pfHb and these followed 
the same trend: HMII (η2 = 0.84; 95% CI: 107.82 – 137.25) and HVAD (η2 = 0.84; 95% CI: 34.71 – 
62.88) significantly higher than the CentriMag (p < 0.0001) at 360 min (Figure 1B). Also, HMII and 
HVAD pfHb was significantly higher than that of the CentriMag after only 60 min (HMII: η2 = 0.63; 
95% CI: 12.35 – 18.87, p < 0.0001 and HVAD: η2 = 0.63; 95% CI:  0.55 – 6.79, p = 0.022). 
Haematology 
All baseline values for red blood cells, platelets, white blood cells and their subsets were reviewed 
against normal reference ranges (25). Haematology assessment was done at all time points for the 
CentriMag (n = 25), HMII (n = 12), and HVAD (n = 11).  Red blood cell counts were unaffected by all 
pumps (Figure 2A). Total leukocyte counts decreased significantly in all pumps over time (linear 




CI: 0.08 - 0.40, p = 0.004) and HVAD (η2 = 0.35; 95% CI: 0.12 - 0.36, p < 0.0001) and compared to 
the static control (Figure 2C). The analysis of the white blood cell subsets revealed that a decline in 
neutrophils is the main contributor to this downward trend. The HVAD granulocyte count was 
significantly lower compared to the static control (η2 = 0.28; 95% CI -0.2442 – -0.9430, p = 0.001) and 
significantly lower compared to the CentriMag in both HMII (η2 = 0.28; 95% CI: -0.0437 – -0.9651, p 
= 0.011) and HVAD (η2 = 0.28; 95% CI: -0.3158 – -1.0145, p = 0.001; at 360 min (Figure 2D). 
Monocyte and lymphocyte counts were unaffected by the pumps (Figures 2E & F). This phenomenon 
of decreased leukocyte counts and increased (false positive) platelet counts is due to the release of 
microparticles from leukocytes, as demonstrated previously (21). To conclude, the HVAD performed 
poorest when it comes to white blood cell handling, especially the handling of granulocytes. 
Platelet Activation 
Platelet activation was measured at all time points for the CentriMag (n = 17), HMII ( n = 8), and HVAD 
(n = 10). Platelet activation was elevated significantly in the HVAD at 240 min (η2 = 0.21; 95% CI: 
0.04 – 0.44, p = 0.017) and 360 min (η2 = 0.30; 95% CI: 0.02 – 0.61, p = 0.035) and the HMII at 240 
min (η2 = 0.21; 95% CI: 0.0826 - 0.5024, p = 0.007) and 360 min (η2 = 0.30; 95% CI: 0.32 – 0.95 , p 
< 0.0001) when compared to the static control (Figure 3).  
Leukocyte-derived Microparticles 
Leukocyte-derived microparticles were assessed at all time points in CentriMag (n = 15), HMII (n = 
10), and HVAD (n = 9). The levels of microparticles were assessed in each pump and divided by those 
found in the static control at 5 min. Both HMII (η2 = 0.79; 95% CI: 18.51 – 33.09, p < 0.0001) and 
HVAD (η2 = 0.79; 95% CI: 30.27 – 44.32, p = 0.004) had elevated levels of LMPs in comparison to 
the static control after 5 mins. When compared to the CentriMag, the HMII and HVAD showed 
significantly increased levels of LMPs at all time-points (p < 0.0001; Figure 4).  
Activated Leukocyte Microparticles 
Our group has previously characterised the activation status of LMPs in ovine blood pumped using the 
CentriMag and identified three distinct populations: CD11bBrightHLADR-; CD11bBrightHLADR+; and 




derived microparticles assessed at all time points in CentriMag (n = 13), HMII (n = 9), and HVAD (n 
= 8). 
The CD11bBrightHLADR- LMPs were increased significantly after 240 min in the HMII and HVAD (p 
< 0.0001 for both; Figure 5A) compared to the CentriMag and static control. The CD11bBrightHLADR+ 
LMPs were increased significantly after 120 min in the HMII (η2 = 0.61; 95% CI: 3.98  – 16.45, p = 
0.003) and HVAD (η2 = 0.61; 95% CI: 15.77 – 30.52, p < 0.0001) (Figure 5B) compared to static 
control. The pattern of activated MPs was changed with the CD11bDullHLADR+. After 120 min, all 
pumps had a significantly increased CD11bDullHLADR+ LMP population (CentriMag, HVAD & HMII: 
p < 0.0001; Figure 5C) compared to the static control.  
To determine whether these activated microparticles were granulocyte-derived, they were analysed for 
MM20A expression (Supplementary Figure 1). Expression of MM20A on the CD11bBrightHLADR- 
population that increased significantly to 360 min in all pumps (Supplementary Figure 1A; CentriMag, 
HMII, & HVAD: p < 0.0001) in keeping with the results in Figure 5A indicate that this microparticle 
subset is granulocyte-derived. This was not the case for CD11bBrightHLADR+ and CD11bDullHLADR+ 
microparticles (Supplementary Figure 1B&C).  
vWF CBA 
The function of von Willebrand factor, as measured by its collagen binding activity, steadily decreased 
with increased pumping time in all pumps ((CentriMag (n = 8), HMII; (n = 6), and HVAD (n = 8)). 
vWF:CBA significantly decreased in the HMII (η2 = 0.451; 95% CI:  -0.02438 – -0.17998, p = 0.013) 
and HVAD (η2 = 0.45; 95% CI: -0.06– -0.20, p = 0.001) after only 5 min of circulation compared to 
the CentriMag (Figure 6A). This trend remained through all time points.   
vWF Immunoblotting 
Immunoblotting indicates a gradual loss of high molecular weight (HMW) vWF multimers with 
increased pumping over time, consistent with reduced collagen binding activity observed in all pumps 






The CentriMag pump has a long successful history of clinical use (26) and we have demonstrated 
previously its consistent low blood damage profile during in vitro testing (19). Here we have used this 
as a baseline comparison for the HMII and HVAD which both produced significantly greater levels of 
blood damage for many of the tested parameters when compared to the CentriMag. Interestingly, the 
blood damage profiles of the HMII and the HVAD differed.  
An increase in haemolysis as calculated by the amount of plasma-free haemoglobin was immediately 
evident after 60 min circulation in the HMII and increased substantially at the end of the 6 h test. In one 
study, patients implanted with the HMII (an axial flow pump) had higher levels of haemolysis than 
patients implanted with the VentrAssist centrifugal pump (27) . In order of least to most haemolysis 
was CentriMag < HVAD < HMII with none of the pumps affecting erythrocyte cell count. The same 
trend was observed with platelet activation with the HMII exhibiting the highest level after 360 min. 
Shared trends in haemolysis and platelet activation are suggestive of a link between the two. Singhal et 
al., demonstrated that extracellular haemoglobin activates platelets through binding to GP1Bα in a 
concentration-dependent manner (28) therefore the high levels of plasma-free haemoglobin in the HMII 
might be at least partially responsible for the higher levels of platelet activation. The HMII was 
compared to the HeartAssist-5 (HA-5) in a study by Chiu et al., using a mock circulatory loop and 
showed a 2.5 fold higher platelet activation than the HA-5 (29). This higher platelet activation was 
attributed to the recirculation and stagnant areas within the HMII leading to thrombus formation within 
the pump (30, 31). 
Leukocytes play a role in both infection and thrombosis making them key elements in adverse events. 
Increased microparticle formation from platelets, leukocytes, and endothelial cells has been 
demonstrated clinically in VAD patients (32). These microparticles express anionic phospholipids, such 
as phosphotidylserine (PS), which are essential for initiating and propagating coagulation (33). PS can 
also induce endothelial damage in inflammatory environments (34). The trend for the emergence of 
LMPs differed to that for haemolysis and platelet activation with the order of least to most LMPs being: 




causing a significant reduction in granulocyte cell numbers and a significant increase in white blood 
cell microparticles as evidenced by an increase in “platelet numbers” (false positive) using the 
haematology analyser and by CD45-labelled microparticles using the flow cytometer. After 360 min 
circulation, the HVAD and HMII showed significantly higher numbers of CD45+ LMPs (p ≤ 0.0001). 
This is a new parameter and its clinical significance is unknown, but recent studies suggest high 
microparticle levels are associated with higher incidence of adverse events (33). 
The leukocyte subset counts seem to correlate better with the activation status of the LMPs characterised 
as CD11bBrightHLADR-, CD11bBrightHLADR+, and CD11bDullHLADR+. The CD11bBrightHLADR- LMPs 
significantly increased after 240 min in the HMII and HVAD. The same trend for CD11bBrightHLADR+ 
was also apparent after 120 min. The CD11bBrightHLADR- LMPs were positive for MM20A 
(Supplementary Figure 1), suggesting that these activated MPs are shed from granulocytes (35) and 
linked to the significant decrease in the granulocyte count in the HMII and HVAD. It is less clear if the 
CD11bBrightHLADR+ are shed from granulocytes but as the CD11bDullHLADR+ lacked MM20A 
expression, they are unlikely to be granulocyte-derived.  Woolley et al., investigated temporal leukocyte 
numbers and MAC-1 expression (a complement receptor consisting of CD11b and CD18) on 
granulocytes from patients implanted with HMII or HVAD. Leukocyte counts increased significantly 
at post-operative day 14 (POD14) but declined to below preoperative level at POD60 in both devices. 
MAC-1 expression on granulocytes was significantly higher in the HMII than the HVAD from POD14 
through to POD60 (36) which correlate with the HMII having the highest number of 
CD11bBrightHLADR- LMPs.  
CD11bDullHLADR+ LMPs showed a different trend, the number of these LMPs increased significantly 
from the static control after 120 min in all pumps, including the CentriMag. This suggests that the act 
of artificially pumping blood in a mock loop activates leukocytes no matter what the design. The cellular 
provenance of the CD11bDullHLADR+ LMPs remains unknown. An increase in HLADR expression is 
a known marker of  T cell activation (37) although the CD11bDullHLADR+ LMPs were not positive for 
the bovine T cell marker MM1A (data not shown). The lack of expression of MM1A doesn’t completely 




number with pumping but these LMPs could still be lymphocyte-derived, but arise from one of the 
minor subsets that might not manifest as a significant effect on total lymphocytes.  Pulsatile-flow 
devices have shown a selective reduction in CD4+ T cells, defective proliferative responses to stimuli 
such as staphylococcal enterotoxin B, and higher levels of apoptosis in CD4+ and CD8+ T cells in 
comparison to medically treated NYHA class IV patients (15, 16, 38, 39). An increase in the number 
of CD11bDullHLADR+ LMPs in all three pumps tested here suggests that they are affected in continuous-
flow devices. Recently, implanted continuous-flow VADs have been reported to increase the percentage 
T regulatory cells (Tregs) (40), which could increase LMP production.   
All pumps showed a progressive decrease in vWF:CBA over time with no significant difference noted 
between the HVAD and HMII. We have previously shown that vWF degradation is influenced by 
varying degrees of shear stress (14). High levels of non-physiological shear stress activate ADAMTS13 
(a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) and unfold vWF 
multimers. Activated ADAMTS13 binds to and cleaves high molecular weight (HMW) vWF, however, 
excess cleavage results in enhanced vWF multimer degradation and reduced vWF activity (41, 42). 
Varying levels of shear stress in the CentriMag, HMII and HVAD could explain different collagen 
binding activity between devices. This observation is consistent with previous findings revealing that 
HMII and HVAD patients have similarly reduced vWF multimers and vWF activity, which might 
explain gastrointestinal bleeding episodes in HMII treated patients (17, 41). Notably, the HMII device 
generates higher levels of shear stress than the newer HeartMate 3 (HM3; Abbott, Thoratec, Pleasanton, 
CA, US) device. As a result, HMII patients show significantly increased HMW vWF degradation 
compared to HM3 patients (43). However, the MOMENTUM3 trial comparing the HMII with the HM3 
showed no significant difference between the devices in terms of gastrointestinal bleeding events within 
six months post-implantation (44). 
 
The HMII and HVAD have been used commonly in clinic since the mid-2000’s after successfully 
completing animal studies and clinical trials (45, 46). Whilst both pumps were tested for haemolysis 




in vitro for their total blood damage capabilities. Our study has shown the HMII causes substantial 
levels of haemolysis, increased platelet activation, high levels of LMPs, and a decrease in the binding 
activity of vWF. The latter has been studied ex vivo and our findings correlate with these. This study 
shows that blood circulated in vitro exhibits a decline in both HMW vWF multimers and vWF CBA. 
These findings are consistent with the enhanced vWF degradation profile and decreased CBA observed 
in HMII and HVAD patients (41, 47). Thus our more extensive in vitro results could relate to the 
prominence of thrombosis and bleeding identified in HMII and HVAD patients.  
The HVAD performed slightly better than the HMII with regards to haemolysis and platelet activation, 
perhaps due to its substantially different design. However, the HVAD generated more CD45+ LMPs, a 
significantly decreased granulocyte count, and an increased population of 
MM20A+CD11bBrightHLADR- MPs that are likely granulocyte-derived. These novel leukocyte assays 
used in our in vitro study reveals that the HVAD may be causing harm to the immune system through 
damaging granulocytes, the key cells for the removal of infectious pathogens. This is apparent clinically 
when comparing infection rates between the pumps - 35% in HVAD (48) and 23% in HMII (49) - and 
provides evidence that leukocyte analysis should be incorporated into VAD development.  
A key limitation of this study which must be considered when interpreting our findings is that these 
pumps were not as originally manufactured. However, it is clear that assessing the total blood damage 
capability of VADs prior to implantation provides a wealth of knowledge that may be beneficial and 
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Figure 1: Haemolysis generated in the CentriMag, HeartMate 2, and HVAD 
Bovine blood diluted to a haematocrit of 30 ± 2% using PBS was loaded into the mock circulatory loops 
for the CentriMag (n = 25), HeartMate 2 (HMII; n = 12), and HVAD (n = 11). A 500 mL bag of bovine 
blood was left in the +37°C water bath as a static control (n = 25). Blood samples were removed every 
hour for 6 hours. A. Average plasma-free haemoglobin (pfHb; mg/dL) levels over time. B. Normalised 
Index of Haemolysis (NIH; g/100L) at 360 min. Mean ± SD; c = significantly different from the 






Figure 2: Haematology for the CentriMag, HeartMate 2, and HVAD 
Bovine blood diluted to a haematocrit of 30 ± 2% using PBS was loaded into the mock circulatory loops 
for the CentriMag (n = 25), HeartMate 2 (HMII; n = 12), and HVAD (n = 11). A 500 mL bag of bovine 
blood was left in the +37°C water bath as a static control (n = 25). Blood samples were removed every 
hour for 6 hours. Average complete cell counts from blood samples run in triplicate were acquired on a 
veterinary haematology analyser. Counts displayed as a fold change from the static control at 5 min. A. 
Erythrocytes; B. Leukocytes; C. Platelets; D. Granulocytes; E. Monocytes; F. Lymphocytes. Mean ± 
SD; s = significantly different from the static control (p < 0.05); c = significantly different from the 







Figure 3: Platelet activation for the CentriMag, HeartMate 2, and HVAD 
Bovine blood diluted to a haematocrit of 30 ± 2% using PBS was loaded into the mock circulatory loops 
for the CentriMag (n = 17), HeartMate 2 (HMII; n = 8), and HVAD (n = 10). A 500 mL bag of bovine 
blood was left in the +37°C water bath as a static control (n = 19). Blood samples were removed every 
hour for 6 hours. Platelet activation (%) was measured over time using flow cytometry. Mean ± SD; s 
= significantly different from the static control (p < 0.05); c = significantly different from the CentriMag 








Figure 4: Leukocyte-derived microparticles in the CentriMag, HeartMate 2, and HVAD 
Bovine blood diluted to a haematocrit of 30 ± 2% using PBS was loaded into the mock circulatory loops 
for the CentriMag (n = 15), HeartMate 2 (HMII; n = 10), and HVAD (n = 9). A 500 mL bag of bovine 
blood was left in the +37°C water bath as a static control (n = 15). Blood samples were removed every 
hour for 6 hours. Number of CD45-positive (CD45+) events with a low side-scatter was measured over 
time using flow cytometry. Mean ± SD; s = significantly different from the static control (p < 0.05); c 
= significantly different from the CentriMag (p < 0.05); hm = significantly different from the HeartMate 






Figure 5: Microparticles expressing activation markers in the CentriMag, HeartMate 2, and 
HVAD 
Bovine blood was diluted to a haematocrit of 30 ± 2% using PBS, loaded into the loops with the 
CentriMag (n = 13), HeartMate 2 (HMII; n = 9), and HVAD (n = 8). Blood from 5, 120, 240, and 360 
min were stained with MM20A, MM1A, CD14, CD21, CD11b, and HLA-DR and the number of 
microparticles with the following expression: A. CD11bBrightHLA-DR-, B. CD11bBrightHLA-DR+, and 
C. CD11bDullHLA-DR+, plotted for each pump type as a fold from the 5 min static control. Mean ± SD; 
s = significantly different from the static control (p < 0.05); c = significantly different from the 






Figure 6: von Willebrand Factor degradation in the CentriMag, HeartMate 2, and HVAD 
Blood from 5, 120, 240, and 360 min was centrifuged to obtain platelet-poor plasma (PPP). Samples 
were analysed for von Willebrand Factor Collagen Binding Activity (vWF:CBA) using ELISA; 
CentriMag (n = 8), HeartMate 2 (HMII; n = 6), and HVAD (n = 8). Immunoblots revealed degradation 
of high molecular weight vWF (HMW:vWF). A. The collagen binding activity (CBA) of vWF over 
time in each pump. B. A representative immunoblot image of HMW:vWF multimer degradation. Mean 
± SD; s = significantly different from the static control (p < 0.05); c = significantly different from the 






Supplementary Figure 1: MM20A expression on activated microparticles 
Expression of the granulocyte marker MM20A on activated microparticles as a fold change from the 
static control at 5 min over time. MM20A expression on the following populations: A. CD11bBrightHLA-
DR-, B. CD11bBrightHLA-DR+, and C. CD11bDullHLA-DR+. Mean ± SD; s = significantly different from 
the static control (p < 0.05); c = significantly different from the CentriMag (p < 0.05). 
 
 
